A granulomatosis with polyangiitis (GPA) blood test panel helps detect the antibody pattern, systemic inflammation, and organ injury associated with this form of small-vessel vasculitis. Common tests include PR3-ANCA and MPO-ANCA, a complete blood count, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), creatinine, estimated glomerular filtration rate, and urinalysis. Additional tests are chosen for symptoms involving the lungs, ears, nose, eyes, nerves, skin, or other organs.
PR3-ANCA is strongly associated with GPA, but it is not a stand-alone diagnostic test. Some people with localized GPA are ANCA-negative, while positive PR3 antibodies can occasionally occur in another disease or without active vasculitis. CRP and ESR can support the presence of inflammation, yet they cannot distinguish GPA from infection and may be normal during limited or treated disease. The panel is most useful when clinicians interpret the results together with symptoms, imaging, urine findings, biopsy evidence, and the trend over time.
- PR3-ANCA is the antibody most closely associated with GPA, but a positive result still requires compatible clinical findings.
- A negative ANCA result does not exclude GPA, especially disease limited to the upper airway, eye, or other localized sites.
- CRP and ESR show inflammation rather than a specific disease, and infection can raise both markers.
- Urinalysis and creatinine are essential even without kidney symptoms, because glomerulonephritis can begin silently.
- ANCA titers should not be used alone to diagnose a relapse or change treatment.
Table of Contents
- What the GPA panel is designed to detect
- PR3-ANCA and MPO-ANCA results
- CRP, ESR, and other inflammation markers
- Kidney, blood count, and organ-safety tests
- How the panel supports a GPA diagnosis
- Using blood tests to assess disease activity
- False positives, mimics, and urgent findings
What the GPA panel is designed to detect
GPA is an ANCA-associated vasculitis that commonly affects the upper respiratory tract, lungs, and kidneys. It can also involve the eyes, ears, skin, joints, peripheral nerves, heart, and central nervous system. The disease causes granulomatous inflammation in the respiratory tract and necrotizing inflammation of small- to medium-sized blood vessels.
A practical blood panel addresses four questions:
- Is a disease-associated ANCA present? Antigen-specific testing identifies antibodies to proteinase 3, or PR3, and myeloperoxidase, or MPO.
- Is there systemic inflammation? CRP and ESR provide broad evidence, while the complete blood count may show anemia, high platelets, or leukocytosis.
- Are the kidneys or other organs being injured? Creatinine, eGFR, urinalysis, liver tests, and selected organ markers answer this.
- Could another condition explain the findings? Cultures, infection testing, ANA, complement, anti-GBM antibodies, and other studies are added when needed.
There is no universal “GPA panel” that is sufficient for every patient. A person with sinus destruction and hearing loss needs a different extension of the workup than someone with coughing blood and rapidly rising creatinine.
The laboratory evaluation also does not replace imaging or biopsy. Chest CT may show nodules, cavities, infiltrates, or airway narrowing. Sinus CT can reveal chronic destructive disease. Tissue from the kidney, lung, nasal cavity, skin, or another affected site can provide decisive evidence, although biopsy sensitivity varies by site.
A broad vasculitis blood test panel is useful when the diagnosis is still open, while a GPA-focused panel gives greater weight to PR3 antibodies and the specific organs GPA often affects.
PR3-ANCA and MPO-ANCA results
PR3-ANCA is the most characteristic blood marker for GPA. Modern testing often begins with high-quality antigen-specific immunoassays for PR3 and MPO rather than using indirect immunofluorescence alone.
PR3-ANCA positive
A positive PR3-ANCA antibody test substantially increases the likelihood of GPA when the person has compatible features such as chronic bloody nasal discharge, destructive sinus disease, lung nodules or cavities, subglottic stenosis, glomerulonephritis, scleritis, or mononeuritis multiplex.
The strength of the result matters less than the clinical fit. A very high antibody level in a patient with active pulmonary-renal disease is compelling. A low-positive result in a person with no vasculitis symptoms may be nonspecific and should not create a diagnosis by itself.
PR3-ANCA positivity is associated with a higher relapse tendency than MPO-ANCA in many patient groups. That association can influence long-term risk discussions, but it cannot predict exactly who will relapse or when.
MPO-ANCA positive
MPO-ANCA is more typical of microscopic polyangiitis, but some people with clinically established GPA are MPO-positive. The phenotype, imaging, biopsy, and organ distribution take priority over forcing every case into an antibody label.
A positive MPO-ANCA result with kidney-limited disease and no granulomatous upper-airway features may fit microscopic polyangiitis better. Conversely, destructive sinus disease and granulomatous inflammation can support GPA despite MPO specificity.
ANCA negative
Negative PR3 and MPO assays do not exclude GPA. ANCA-negative disease is more likely when inflammation is localized to the upper airway, orbit, ear, or a single organ. Treatment can also reduce antibody levels.
When suspicion remains high, clinicians rely on imaging, repeated urine assessment, examination by the relevant specialist, and biopsy of an active site. Repeating ANCA with a different method is occasionally useful, but repeatedly testing without new clinical evidence rarely solves an uncertain diagnosis.
IFA patterns
Indirect immunofluorescence may report a cytoplasmic c-ANCA pattern or a perinuclear p-ANCA pattern. c-ANCA often corresponds to PR3, while p-ANCA often corresponds to MPO, but the relationship is not exact. An ANCA by IFA pattern should be paired with antigen-specific results whenever possible.
CRP, ESR, and other inflammation markers
CRP and ESR are useful context markers, not diagnostic markers. Both can rise during active GPA, but both also rise with bacterial infection, other autoimmune disease, tissue injury, cancer, and many common illnesses.
C-reactive protein
CRP is produced by the liver in response to inflammatory signaling. It can rise within hours and often falls relatively quickly when inflammation improves. A CRP result may help track a patient whose previous flares consistently raised CRP.
A normal CRP does not rule out active localized GPA. Eye inflammation, subglottic stenosis, chronic sinus activity, or smoldering kidney disease may occur with little systemic marker elevation. CRP can also remain high because of infection while vasculitis is controlled.
Erythrocyte sedimentation rate
ESR measures how quickly red blood cells settle in a tube. It changes more slowly than CRP and is influenced by age, anemia, pregnancy, kidney disease, and blood-protein changes. An ESR test may stay elevated after symptoms improve.
Because the two markers behave differently, clinicians often order both at diagnosis and during uncertain episodes. Discordant results are common and not automatically worrisome. For example, ESR may remain high because of anemia while CRP has normalized.
Complete blood count and related markers
Active inflammation can cause normocytic anemia, elevated platelets, and a high white blood cell count. Glucocorticoids can raise neutrophils even when infection is absent. Cyclophosphamide, rituximab, azathioprine, methotrexate, and other treatments can lower blood counts or alter immune cells.
The complete blood count therefore serves two roles: it may support active inflammation, and it monitors treatment toxicity. Eosinophilia is not typical of GPA and may suggest EGPA, allergy, medication reaction, or another eosinophilic condition when pronounced.
Kidney, blood count, and organ-safety tests
Kidney assessment is mandatory because GPA glomerulonephritis can be present before swelling, reduced urine, or pain appears. The highest-value tests are serum creatinine, eGFR, urinalysis with microscopy, and a urine protein measurement.
Concerning findings include:
- New blood and protein in urine
- Dysmorphic red blood cells
- Red blood cell casts
- Rising creatinine or falling eGFR
- Reduced urine output, fluid retention, or high potassium
A normal creatinine does not guarantee normal kidneys. Early glomerulonephritis may first appear as microscopic hematuria and proteinuria. Conversely, stable chronic kidney damage may leave creatinine elevated even when vasculitis is in remission. The trend and urine sediment help distinguish active inflammation from permanent loss of function.
When rapidly progressive glomerulonephritis is possible, clinicians may also order anti-GBM antibodies, ANA, anti-dsDNA, C3 and C4, hepatitis tests, cryoglobulins, blood cultures, and infection studies. A GBM antibody panel is particularly important when pulmonary hemorrhage accompanies severe kidney injury.
Other organ-directed tests may include:
| Clinical concern | Possible evaluation |
|---|---|
| Coughing blood or new lung opacities | Chest CT, oxygen measurement, hemoglobin trend, bronchoscopy when needed |
| Eye pain, redness, or vision change | Urgent ophthalmologic examination |
| Hearing loss, hoarseness, or stridor | ENT examination, audiology, airway imaging or endoscopy |
| Weakness, numbness, or foot drop | Nerve conduction studies, electromyography, possible biopsy |
| Chest pain or heart failure symptoms | ECG, troponin, natriuretic peptide, echocardiography, cardiac imaging |
Before immunosuppression, screening for hepatitis, tuberculosis risk, vaccination status, pregnancy when relevant, and baseline immunoglobulin levels may be needed. These are treatment-safety tests rather than markers of GPA itself.
How the panel supports a GPA diagnosis
A diagnosis is built from the pattern of disease. Common combinations include chronic sinus or nasal inflammation, ear disease, pulmonary nodules or cavities, glomerulonephritis, scleritis, skin vasculitis, and peripheral neuropathy.
The 2022 ACR/EULAR classification criteria assign weighted points to PR3-ANCA or c-ANCA positivity, nasal symptoms, cartilaginous involvement, conductive or sensorineural hearing loss, lung nodules or cavities, granuloma on biopsy, and pauci-immune glomerulonephritis. MPO-ANCA, eosinophilia, and certain other features subtract points. These criteria classify patients for research after mimics have been excluded and small- or medium-vessel vasculitis has been established. They are not designed as a public self-test or the sole basis for diagnosis.
Biopsy remains valuable when it can be obtained safely and is likely to answer the question. Kidney biopsy often has high yield in active glomerulonephritis and typically shows pauci-immune necrotizing crescentic disease. Nasal biopsies are easier to obtain but may show only nonspecific inflammation. Lung or orbital tissue may be more informative but carries greater procedural risk.
A positive PR3-ANCA can sometimes reduce the need for invasive tissue when the clinical picture is classic and urgent treatment is required. However, biopsy may still help exclude infection, cancer, cocaine-related injury, IgG4-related disease, or another inflammatory disorder.
Diagnosis should be prompt but careful. Immunosuppression can be lifesaving in active GPA, yet it can worsen an untreated infection that mimics vasculitis.
Using blood tests to assess disease activity
Disease activity is best judged by new or worsening manifestations attributable to vasculitis. Blood tests support that judgment but do not define it.
ANCA trends
A rising PR3-ANCA level can be associated with a greater chance of future relapse, especially in some patients with kidney disease. The prediction is not precise enough to treat the number alone. Some patients remain persistently positive in stable remission, while others relapse without a clear rise.
A treatment change based only on ANCA can expose a patient to unnecessary infection, low immunoglobulins, infertility risk, bladder toxicity, or other adverse effects. Clinicians usually look for corroborating symptoms, urine changes, imaging, or organ markers.
CRP and ESR trends
CRP and ESR are most informative when compared with that individual’s established pattern. If prior flares caused a marked CRP rise, a new rise deserves attention. If the person has historically active localized disease with normal markers, normal results should not reassure too strongly.
An unexpected marker rise should also trigger an infection review. Sinus infection, pneumonia, urinary infection, line infection, and opportunistic infection can resemble relapse, particularly during immune-suppressing treatment.
Kidney trends
Urinalysis and creatinine are critical but require nuance. Persistent microscopic blood can remain after glomerular injury and does not always mean active vasculitis. A new increase in blood, protein, cellular casts, or creatinine is more concerning. Kidney biopsy may be needed when chronic damage, medication toxicity, infection, and active glomerulonephritis cannot be separated.
Damage versus activity
Not every ongoing symptom reflects active inflammation. Hearing loss, saddle-nose deformity, chronic kidney impairment, neuropathic pain, and airway scarring may persist after the disease is controlled. Increasing immunosuppression will not reverse established damage and may create harm. The distinction between active disease and damage is one of the most important reasons the panel must be interpreted clinically.
False positives, mimics, and urgent findings
PR3-ANCA and MPO-ANCA are highly useful but not perfectly specific. Positive results can occur with infection, inflammatory bowel disease, autoimmune liver disease, drug exposure, and other autoimmune conditions. Cocaine contaminated with levamisole can cause destructive nasal disease, skin findings, and unusual ANCA patterns that mimic GPA.
Major GPA mimics include:
- Bacterial or fungal sinus and lung infection
- Tuberculosis or nontuberculous mycobacterial disease
- Endocarditis with immune kidney injury
- Malignancy involving the airway, lung, kidney, or orbit
- Cocaine-related midline destructive disease
- IgG4-related disease
- Sarcoidosis
- Microscopic polyangiitis or anti-GBM disease
- Relapsing polychondritis
Cultures and tissue microbiology are sometimes as important as pathology. A biopsy sent only for histology may miss an infection that requires culture, staining, or molecular testing.
Urgent assessment is needed for coughing blood, severe breathlessness, rapidly rising creatinine, reduced urine, new weakness or foot drop, severe eye pain, vision loss, stridor, chest pain, or neurologic symptoms. These findings can indicate organ-threatening disease even if CRP, ESR, or ANCA levels are not dramatically abnormal.
For routine monitoring, patients benefit from keeping a record of baseline creatinine, usual urine findings, PR3 or MPO status, and which markers changed during previous flares. That personal pattern is often more useful than comparing a single result with a generic “normal” value.
References
- 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Granulomatosis with Polyangiitis 2022 (Guideline)
- EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update 2024 (Guideline)
- KDIGO 2024 Clinical Practice Guideline for the Management of Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis 2024 (Guideline)
- Granulomatosis with polyangiitis: clinical characteristics and updates in diagnosis 2024 (Review)
- 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis 2021 (Guideline)
- Systematic literature review informing the 2022 update of the EULAR recommendations for the management of ANCA-associated vasculitis: part 1—treatment of granulomatosis with polyangiitis and microscopic polyangiitis 2023 (Systematic Review)
Disclaimer
A GPA blood test panel cannot diagnose, exclude, or grade vasculitis without symptoms, examination, imaging, urine assessment, and sometimes biopsy. ANCA, CRP, and ESR may remain abnormal in remission or appear normal during active disease. Coughing blood, rapidly reduced kidney function, vision change, severe breathing difficulty, stridor, or new neurologic weakness requires urgent medical care.
